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Efficacy of carboplatin (C ) and etoposide (E ) for extensive stage 
small cell lung cancer (ED-SCLC)
Yilmaz, Ufuk; Halilcolar, Huseyin; Yapicioglu, Sena;  
Yildirim, Yasemin; Unsal, Ipek; Mahlec, Ceyda 
Suat Seren Chest Disease and Surgery Training and Research Hospital, 
Izmir, Turkey
Background: Standard chemotherapy for SCLC is considered to be a 
cisplatin based combination. C has broad spectrum anti-tumor activ-
ity and is commonly used as a less toxic alternative to cisplatin. The 
purpose of this study is to investigate the activity and toxicity of C and 
E in patients (pts) with previously untreated ED- SCLC. 
Methods: Patients characteristics included pathologically diagnosed 
extensive SCLC, measurable or evaluable disease, ECOG performance 
status (PS) 0-3, and adequate organ function. Chemotherapy consisted 
of ( C ) AUC 6 IV day 1, ( E ) 100 mg/m2IV day 1-3. This schedule was 
repeated every 21 days for maximum 6 cycles. Data were collected pro-
spectively. Survival data was calculated from date of treatment to date 
of death or last known follow up. Kaplan-Meier curves and Log Rank 
test were used for studying survival rates.
Results: From 01/01 to 11/06, 56 Chemotherapy and radiotherapy 
naive pts were enrolled and 52 were evaluable. Patients characteristics 
were as follows: median age 62 years (range 39-76); 50 male and 2 
female; ECOG PS 0-1 in 43 pts, PS 2-3 in 9 pts. 14 pts had multi-organ 
metastasis. 33 patients died. Seven patients lost to follow up. A total of 
243 cycles were administered: median 4.68 (range 1-6). Dose reduc-
tions took place in 2.8% of cycles. The overall response rate was 71% 
(25% CR, 46% PR). Median overall survival was 337 days (95% [CI 
272-401]), one-year and two years survival were 44.8% and 13.3%, 
respectively. Log Rank test demonstrated that multi-organ metastasis 
lead to a trend to the poor survival (P=0.055). Grade III-IV neutrope-
nia, leukopenia, thrombocytopenia, anemia were detected in 16%, 6%, 
4.5%, 3.7% of courses, respectively. Febrile neutropenia was developed 
in 5 patients. There was no toxic death. Non-hematological toxicity was 
generally mild.
Conclusions: On the basis of these results, It seems that C+E is active 
and tolerable in ED-SCLC patients and our outcomes are in line with 
other published platinum-based studies.
SCLC: Molecular Targeted Therapy
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N-cadherin, a potential novel therapeutic target in small cell lung 
cancer
Batus, Marta; Coon, John; Kaiser, Kelly A.; Ahmed, Samina; Avery, 
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Background: New treatment ideas are needed in small cell lung cancer 
(SCLC). N-cadherin which is associated with increased tumor invasive-
ness is a potential novel therapeutic target. It seems reasonable to test 
recently developed cyclic peptide N-cadherin antagonists in tumors 
with high N-cadherin expression, and it seemed likely that high N-cad-
herin expression would occur more frequently in aggressive tumors like 
SCLC. Our objective was to determine the frequency and biological 
signiﬁcance of N-cadherin expression in SCLC.
Methods: We retrospectively analyzed 86 patients with small cell 
lung cancer, most of whom received treatment: chemotherapy with 
or without radiation. We reviewed their clinical charts and obtained: 
date of diagnosis, age, gender, performance status, treatment dates and 
treatment response (CR/PR, stable disease, progression), and death or 
last encounter date. We also analyzed their pathology specimens for 
frequency of expression of N-cadherin and grouped them into three cat-
egories: no expression, some expression of N-cadherin >1% but <35%, 
and strong expression 36-100%. Subsequently, we determined the 
correlation between the N-cadherin frequency groups and the overall 
survival for all 86 patients. We also determined the time to progression 
in a subset of 56 patients (with available treatment response data).
Results: Out of the 86 patients, 18 (21%) did not express N-cadherin, 
10 (11.6%) patients showed >1% but <35% expression of N-cadherin, 
and 58 (67.4%) had a strong expression >36%-100%. There was no 
association found between N-cadherin expression and overall survival 
using either the Log-Rank Test or the Wilcoxon Test. In the subset of 
56 patients with available treatment response data there was no associa-
tion between N-cadherin expression and progression free survival. 
Conclusions: N-cadherin was expressed relatively frequently in this 
group of SCLC patients, and these results suggest that phase II trials of 
the novel cyclic peptide N-cadherin antagonists are warranted in SCLC. 
N-cadherin did not appear to have prognostic value in our study.
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Once a day (QD) thoracic 3D conformal radiotherapy (XRT) for 
patients with limited stage small-cell lung cancer (SCLC) treated 
concurrently with etoposide and cisplatin (EP): results of a single 
institution retrospective experience.
Couraud, Sebastien1 Direito, Ana1 Martel Lafay, Isabelle2 Arpin, 
Dominique1 Depagne, Corinne1 Nesme, Pascale1 Guerin, Jean-Claude1 
Perol, Maurice1 
1 Hospices Civils de Lyon, Lyon, France 2 Léon Bérard Regional Can-
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Background: Standard treatment of limited-stage SCLC is based on 
EP chemotherapy (CT) given concurrently with early twice a day (BID) 
thoracic XRT (45 Gy in 30 fractions) and prophylactic cranial irradia-
tion (PCI) in case of complete response (CR). BID thoracic XRT is dif-
ﬁcult in common practice and often causes severe esophagitis. Option 
of a more convenient QD schedule with a higher dose conformal 3D 
XRT needs to be studied. 
Patients and Methods: Patients (pts) with limited-stage SCLC re-
ceived P (100 mg/m2 d1) - E (100 mg/m2 d1-3) for 4 courses adminis-
tered every 3 weeks with a 20% dose reduction during XRT (cycle 2 
and 3). QD 3D conformal thoracic XRT began concurrently with the 
second course and delivered 60 Gy (30 fractions of 2 Gy) in 6 weeks. 
PCI (24 Gy, 12 fractions) was given for complete responders. Results 
were retrospectively analysed.
